Dr Stephen Jones is stepping down as chief executive of Evocutis.
Dr Jones has a new job at an unrelated healthcare company. He will stay at Evocutis until the beginning of October or when a replacement is appointed, if that is earlier. Evocutis is at the stage of its evolution where it requires more commercial expertise. A number of large companies have shown interest in Evocutisí products but there is little in the way of revenues.
Evocutis is the new name for Syntopix following its purchase of Leeds Skin in May 2011. The company more than doubled its interim revenues from £161,000 to £344,000 in the six months to January 2012. The loss was reduced from £557,000 to £434,000.
There was £1.85m in the bank at the end of January 2012.
At 2.12p a share, down 0.12p, Evocutis is valued at £3.68m.
© 2007 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Geospatial data analyser 1Spatial is raising £18m at 6p a share in order to help finance the purchase of 75.14% of Star-Apic and the opening of a sales and support centre in the Middle East.
Advanced Power Components (APC) is buying out the minority shareholders in energy saving technologies supplier Minimise.
Warehouse data systems services provider Belgravium Technologies says that the current financial year has started slowly.
Online conveyancing services provider In-Deed Online says that trading remains challenging.